Journal article

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

WN Kernan, CM Viscoli, KL Furie, LH Young, SE Inzucchi, M Gorman, PD Guarino, AM Lovejoy, PN Peduzzi, R Conwit, LM Brass, GG Schwartz, HP Adams, L Berger, A Carolei, W Clark, B Coull, GA Ford, D Kleindorfer, JR O'Leary Show all

New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2016

Grants

Awarded by National Institute of Neurological Disorders and Stroke


Awarded by National Institute for Health Research


Funding Acknowledgements

Supported by a grant (U01NS044876) from the National Institute of Neurological Disorders and Stroke. Pioglitazone and placebo were provided by Takeda Pharmaceuticals International.Dr. Young reports receiving grant support through his institution from Merck and Mifcor; Dr. Inzucchi, receiving fees for serving on advisory boards from Merck, Janssen, Sanofi, Poxel, Boehringer Ingelheim, Eli Lilly, and AstraZeneca, fees for serving on a data monitoring committee from Novo Nordisk and Intarcia, and fees for serving on a steering committee from Lexicon, serving as an expert witness on behalf of Takeda in a patent litigation deposition, and participating in projects for which funding for continuing medical education has been provided to Yale University by Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Abbott, Merck, and Sanofi; Dr. Peduzzi, receiving consulting fees from Millennium; Dr. Schwartz, receiving grant support from Cerenis, Roche, Resverlogix, Sanofi, and the Medicines Company; Dr. Ford, receiving fees for serving on a trial steering committee from Lundbeck, fees for serving on a data safety monitoring board from Cerevast, fees for serving on advisory boards from Pfizer, Athersys, and Daiichi Sankyo, consulting fees from Pfizer, and lecture fees and travel support from AstraZeneca and Boehringer Ingelheim; Dr. Ringleb, receiving fees for serving on advisory boards from Boehringer Ingelheim, Covidien, Bayer, and Daiichi Sankyo and lecture fees and travel support from Boehringer Ingelheim, Bayer, and Daiichi Sankyo; Dr. Spence, receiving consulting and lecture fees from Bayer and Bristol-Myers Squibb, serving as an officer of and having an equity interest in Vascularis, and performing contract research for Bayer, Bristol-Myers Squibb, Pfizer, Acasti Pharma, POM Wonderful, CVRx, AGA Medical, and W.L. Gore. No other potential conflict of interest relevant to this article was reported.